Carrie Lenneman is a Cardiology physician. OpenAlex indexes 26 publications with 897 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1717 6th Ave S
Birmingham, AL 352331801
Telephone
800-822-8816Registry record last updated 29 Jun 2023.
Clinical trials
- Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Sponsor: Vanderbilt University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
77.4%Beta blocker27.3%Metoprolol Succinate64%Carvedilol22%Metoprolol Tartrate8%Nebivolol Hcl3%Propranolol Hcl3%Part D<11 patientsStatin10.9%Atorvastatin Calcium51%Rosuvastatin Calcium39%Pravastatin Sodium11%Part D<11 patients+ 12 more classes in this area
Blood & clotting
13.2%Factor Xa inhibitor12.4%Eliquis100%Part D≥37 patientsP2Y12 inhibitor0.9%Clopidogrel100%Part D<11 patientsMetabolism & gastrointestinal
9.4%SGLT2 inhibitor6.3%Jardiance100%Part D≥31 patientsPotassium supplement3.1%Potassium Chloride100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- THE GLOBAL CARDIO-ONCOLOGY REGISTRY (G-COR) US PILOT STUDY: EARLY COHORT BREAST CANCER PATIENTS DEMOGRAPHICS AND EXERCISE HABITS
Journal of the American College of Cardiology
2024 - Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases
Current Cardiology Reports
2023 - OVERLAPPING SYNDROME OF MYOSITIS, HEPATITIS AND COMPLETE HEART BLOCK IN A ESOPHAGEAL CANCER PATIENT AFTER IMMUNOTHERAPY
Journal of the American College of Cardiology
2023 - Innovations in Cardio-oncology Resulting from the COVID-19 Pandemic
Current Treatment Options in Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”